An official website of the United States government
The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before
sharing sensitive information, make sure you’re on a federal
government site.
The site is secure.
The https:// ensures that you are connecting to the
official website and that any information you provide is encrypted
and transmitted securely.
Comprehensive neuroimaging ancillary evaluation: fluorodeoxyglucose–positron emission tomography, neuromelanin and nigrosome‐1 magnetic resonance imaging,…
FIG 1
Comprehensive neuroimaging ancillary evaluation: fluorodeoxyglucose–positron emission tomography, neuromelanin and nigrosome‐1 magnetic resonance imaging, and 99mTc‐TRODAT‐1 (Technetium‐99m labeled tropane derivative) single‐photon emission computed tomography). (A–C) Fluorodeoxyglucose–positron emission tomography scan axial slices (through the thalamus, striatum, and corona radiata) show cerebral glucose metabolism within normal limits in the basal ganglia and cortical regions. (D–G) Three‐dimensional stereotactic surface projection (3d‐SSP) projection of the cortical radiotracer uptake to a lateral and medial surface perspective of both hemispheres shows normal glucose metabolism. (H) Normal neuromelanin content is seen in an axial magnetic resonance imaging slice of the midbrain through the substantia nigra. (I) Nigrossome‐1 and its related “swallow‐tail” sign are readily identifiable in both cerebral peduncles. (J–M) Nigrostriatal denervation at the left mid‐putamen (semiquantification of dopamine transporter binding—0.60), contralateral to the most significant clinically affected side. The specific dopamine transporter binding potential in the basal ganglia is calculated as the difference between dorsal putamen activity (PUT) and the reference region, that is, the occipital activity (OA), divided by the OA: (PUT−OA)/OA. [Color figure can be viewed at wileyonlinelibrary.com]
Méndez‐Guerrero A, Laespada‐García MI, Gómez‐Grande A, et al. Acute hypokinetic‐rigid syndrome following SARS‐CoV‐2 infection. Neurology [published online ahead of print July 8, 2020]. 10.1212/WNL.0000000000010282.
-
DOI
-
PubMed
Munhoz RP, Pedroso JL, Nascimento FA, et al. Neurological complications in patients with SARS‐CoV‐2 infection: a systematic review. Arq Neuropsiquiatr 2020;78(5):290–300. 10.1590/0004-282x20200051.
-
DOI
-
PubMed
Ellul MA, Benjamin L, Singh B, et al. Neurological associations of COVID‐19. Lancet Neurol 2020;19(9):767–783. 10.1016/S1474-4422(20)30221-0.
-
DOI
-
PMC
-
PubMed
Paniz‐Mondolfi A, Bryce C, Grimes Z, et al. Central nervous system involvement by severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2). J Med Virol 2020;92(7):699–702. 10.1002/jmv.25915.
-
DOI
-
PMC
-
PubMed
Hoffman LA, Vilensky JA. Encephalitis lethargica: 100 years after the epidemic. Brain 2017;140(8):2246–2251. 10.1093/brain/awx177.
-
DOI
-
PubMed